Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 55-62

  Schramm, Alexander ^a   Mierswa, Ingo ^b   Kaderali, Lars ^c   Morik, Katharina ^d   Eggert, Angelika ^a   Schulte, Johannes H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RAPIDMINER GMBH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

CASPAR; Expression profiling; Neuroblastoma; Reanalysis; SVM

Indexed keywords

ARTICLE; BAYESIAN LEARNING; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CANCER SURVIVAL PREDICTION USING AUTOMATIC RELEVANCE DETERMINATION PROGRAM; CHILD; CONTROLLED STUDY; DATA MINING; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC ALGORITHM; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; PERFORMANCE MEASUREMENT SYSTEM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPEAT PROCEDURE; RISK ASSESSMENT; SUPPORT VECTOR MACHINE; SURVIVAL TIME; VALIDATION PROCESS;

ALGORITHMS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67649397388     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.052     Document Type: Article

References (27)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
2. Maris J.M., Hogarty M.D., Bagatell R., and Cohn S.L. Neuroblastoma. Lancet 369 (2007) 2106-2120
3. Park J.R., Eggert A., and Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr. Clin. North. Am. 55 (2008) 97-120
4. Vandesompele J., Baudis M., De Preter K., Van Roy N., Ambros P., Bown N., Brinkschmidt C., Christiansen H., Combaret V., Lastowska M., Nicholson J., O'Meara A., Plantaz D., Stallings R., Brichard B., Van den Broecke C., De Bie S., De Paepe A., Laureys G., and Speleman F. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 23 (2005) 2280-2299
5. Schwab M., Westermann F., Hero B., and Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4 (2003) 472-480
6. Berwanger B., Hartmann O., Bergmann E., Bernard S., Nielsen D., Krause M., Kartal A., Flynn D., Wiedemeyer R., Schwab M., Schafer H., Christiansen H., and Eilers M. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2 (2002) 377-386
7. Oberthuer A., Berthold F., Warnat P., Hero B., Kahlert Y., Spitz R., Ernestus K., Konig R., Haas S., Eils R., Schwab M., Brors B., Westermann F., and Fischer M. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 24 (2006) 5070-5078
8. Ohira M., Oba S., Nakamura Y., Isogai E., Kaneko S., Nakagawa A., Hirata T., Kubo H., Goto T., Yamada S., Yoshida Y., Fuchioka M., Ishii S., and Nakagawara A. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7 (2005) 337-350
9. Schramm A., Vandesompele J., Schulte J.H., Dreesmann S., Kaderali L., Brors B., Eils R., Speleman F., and Eggert A. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin. Cancer Res. 13 (2007) 1459-1465
10. Schulte J.H., Horn S., Otto T., Samans B., Heukamp L.C., Eilers U.C., Krause M., Astrahantseff K., Klein-Hitpass L., Buettner R., Schramm A., Christiansen H., Eilers M., Eggert A., and Berwanger B. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int. J. Cancer 122 (2008) 699-704
11. Chen Q.R., Song Y.K., Wei J.S., Bilke S., Asgharzadeh S., Seeger R.C., and Khan J. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics (2008)
12. Kaderali L., Zander T., Faigle U., Wolf J., Schultze J.L., and Schrader R. CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data. Bioinformatics 22 (2006) 1495-1502
13. Schulte J.H., Schramm A., Klein-Hitpass L., Klenk M., Wessels H., Hauffa B.P., Eils J., Eils R., Brodeur G.M., Schweigerer L., Havers W., and Eggert A. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24 (2005) 165-177
14. Schramm A., Schulte J.H., Klein-Hitpass L., Havers W., Sieverts H., Berwanger B., Christiansen H., Warnat P., Brors B., Eils J., Eils R., and Eggert A. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24 (2005) 7902-7912
15. Mierswa I., Wurst M., Klinkenberg R., Scholz M., and Euler T. RapidMiner/YALE: Rapid Prototyping for Complex Data Mining Tasks. In: Eliassi-Rad T., Ungar L.H., Craven M., and Gunopulos D. (Eds). Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (2006), ACM Press, New York 935-940
16. Cohn S.L., Look A.T., Joshi V.V., Holbrook T., Salwen H., Chagnovich D., Chesler L., Rowe S.T., Valentine M.B., Komuro H., et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res. 55 (1995) 721-726
17. Tonini G.P., Boni L., Pession A., Rogers D., Iolascon A., Basso G., Cordero di Montezemolo L., Casale F., Perri P., Mazzocco K., Scaruffi P., Lo Cunsolo C., Marchese N., Milanaccio C., Conte M., Bruzzi P., and De Bernardi B. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J. Clin. Oncol. 15 (1997) 85-93
18. Vapnik V.N. The Nature of Statistical Learning Theory (1995), Springer
19. Hastie T.T., Tibshirani T., and Friedman J. The Elements of Statistical Learning (2001), Springer
20. Varma S., and Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 7 (2006) 91
21. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., Matthay K., Buckley J., Ortega A., and Seeger R.C. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl. Cancer Inst. 98 (2006) 1193-1203
22. Shmueli O., Gdalyahu A., Sorokina K., Nevo E., Avivi A., and Reiner O. DCX in PC12 cells: CREB-mediated transcription and neurite outgrowth. Hum. Mol. Genet. 10 (2001) 1061-1070
23. Oltra S., Martinez F., Orellana C., Grau E., Fernandez J.M., Canete A., and Castel V. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn. Mol. Pathol. 14 (2005) 53-57
24. Viprey V.F., Lastowska M.A., Corrias M.V., Swerts K., Jackson M.S., and Burchill S.A. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J. Pathol. 216 (2008) 245-252
25. Schilling F.H., Spix C., Berthold F., Erttmann R., Fehse N., Hero B., Klein G., Sander J., Schwarz K., Treuner J., Zorn U., and Michaelis J. Neuroblastoma screening at one year of age. New Engl. J. Med. 346 (2002) 1047-1053
26. Ohira M., Morohashi A., Inuzuka H., Shishikura T., Kawamoto T., Kageyama H., Nakamura Y., Isogai E., Takayasu H., Sakiyama S., Suzuki Y., Sugano S., Goto T., Sato S., and Nakagawara A. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 22 (2003) 5525-5536
27. Oberthuer A., Kaderali L., Kahlert Y., Hero B., Westermann F., Berthold F., Brors B., Eils R., and Fischer M. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin. Cancer Res. 14 (2008) 6590-6601